U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O.Zn
Molecular Weight 81.408
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Zinc oxide

SMILES

[O--].[Zn++]

InChI

InChIKey=RNWHGQJWIACOKP-UHFFFAOYSA-N
InChI=1S/O.Zn/q-2;+2

HIDE SMILES / InChI
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Characterization and inhibition of SARS-coronavirus main protease.
2006
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
2011 Jun
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:38:40 GMT 2023
Edited
by admin
on Fri Dec 15 15:38:40 GMT 2023
Record UNII
SOI2LOH54Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Zinc oxide
EP   FCC   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
Zinc oxide [WHO-DD]
Common Name English
ZINC OXIDE COMPONENT OF VUSION
Common Name English
C.I. 77947
Common Name English
ZINC OXIDE [USP-RS]
Common Name English
ZINC WHITE
Common Name English
ZINC (AS ZINC OXIDE) [VANDF]
Common Name English
ZINC OXIDE COMPONENT OF CALAMINE
Common Name English
CALAMINE COMPONENT ZINC OXIDE
Common Name English
CI 77947
INCI  
INCI  
Official Name English
C.I. PIGMENT WHITE 4
Common Name English
ZINCUM OXYDATUM
HPUS  
Common Name English
ZINC OXIDE NEUTRAL [USP MONOGRAPH]
Common Name English
ZINC OXIDE [MART.]
Common Name English
ZINC OXIDE EMULSION [VANDF]
Common Name English
ZINC OXIDE [WHO-IP]
Common Name English
ZINC PASTE [VANDF]
Common Name English
ZINC OXIDE [HSDB]
Common Name English
ZINC OXIDE [INCI]
Common Name English
ZINC OXIDE [ORANGE BOOK]
Common Name English
ZINC OXIDE [FCC]
Common Name English
ZINC OXIDE [USP IMPURITY]
Common Name English
ZINC OXIDE [EP MONOGRAPH]
Common Name English
ZINC OXIDE [II]
Common Name English
ZINCI OXYDUM [WHO-IP LATIN]
Common Name English
ZINC OXIDE [JAN]
Common Name English
ZINC OXIDE [VANDF]
Common Name English
CI 77947 [INCI]
Common Name English
ZINC (AS OXIDE) [VANDF]
Common Name English
VUSION COMPONENT ZINC OXIDE
Common Name English
ZINC PASTE
VANDF  
Common Name English
ZINC OXIDE [MI]
Common Name English
ZINCUM OXYDATUM [HPUS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 178.3297
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 175.300
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 175.380
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 177.1460
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 177.1900
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
FDA ORPHAN DRUG 142401
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 310.531
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 352.20
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 352.10
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
WHO-VATC QA07XA91
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
Food Contact Sustance Notif, (FCN No.) FCN NO. 193
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
EPA PESTICIDE CODE 88502
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 347.10
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
NCI_THESAURUS C851
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 346.18
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 177.1350
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 176.170
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
Code System Code Type Description
DRUG BANK
DB09321
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
MERCK INDEX
m11617
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY Merck Index
RS_ITEM_NUM
1724747
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
SMS_ID
100000089333
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
PUBCHEM
3007857
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
WIKIPEDIA
ZINC OXIDE
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ZINC OXIDE
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY Description: A white or faintly yellowish white, very fine, amorphous powder, free from grittiness; odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in hydrochloric acid (~70 g/l) TS. Category: Mild astringent used topically as a protective. Storage: Zinc oxide should be kept in a well-closed container. Additional information: Zinc oxide gradually absorbs carbon dioxide from the air. Definition: Zinc oxide contains not less than 99.0% and not more than 100.5% of ZnO, calculated with reference to the freshly ignited substance.
EVMPD
SUB12623MIG
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID7035016
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
MESH
D015034
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
DRUG CENTRAL
4240
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
NCI_THESAURUS
C949
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
HSDB
5024
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
RXCUI
11423
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY RxNorm
CAS
1314-13-2
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
CHEBI
36560
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201128
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
FDA UNII
SOI2LOH54Z
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
DAILYMED
SOI2LOH54Z
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-222-5
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
Related Record Type Details
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of Zinc oxide
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966